Boston Scientific Corporation
BSX · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $16,747,000 | $14,240,000 | $12,682,000 | $11,888,000 |
| % Growth | 17.6% | 12.3% | 6.7% | – |
| Cost of Goods Sold | $6,480,000 | $5,409,000 | $4,968,000 | $4,427,000 |
| Gross Profit | $10,267,000 | $8,831,000 | $7,714,000 | $7,461,000 |
| % Margin | 61.3% | 62% | 60.8% | 62.8% |
| R&D Expenses | $1,615,000 | $1,414,000 | $1,323,000 | $1,204,000 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $5,984,000 | $5,190,000 | $4,520,000 | $4,286,000 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $33,000 | $46,000 | $47,000 | $49,000 |
| Operating Expenses | $7,632,000 | $6,650,000 | $5,890,000 | $5,539,000 |
| Operating Income | $2,635,000 | $2,181,000 | $1,824,000 | $1,922,000 |
| % Margin | 15.7% | 15.3% | 14.4% | 16.2% |
| Other Income/Exp. Net | -$353,000 | -$196,000 | -$683,000 | -$846,000 |
| Pre-Tax Income | $2,282,000 | $1,985,000 | $1,141,000 | $1,076,000 |
| Tax Expense | $436,000 | $393,000 | $443,000 | $36,000 |
| Net Income | $1,854,000 | $1,593,000 | $698,000 | $1,040,000 |
| % Margin | 11.1% | 11.2% | 5.5% | 8.7% |
| EPS | 1.26 | 1.081 | 0.449 | 0.693 |
| % Growth | 16.6% | 140.8% | -35.2% | – |
| EPS Diluted | 1.25 | 1.073 | 0.446 | 0.687 |
| Weighted Avg Shares Out | 1,471,500 | 1,453,000 | 1,430,500 | 1,422,300 |
| Weighted Avg Shares Out Dil | 1,485,900 | 1,463,500 | 1,439,700 | 1,433,800 |
| Supplemental Information | – | – | – | – |
| Interest Income | $107,000 | $22,000 | $10,000 | $4,000 |
| Interest Expense | $387,000 | $272,000 | $464,000 | $349,000 |
| Depreciation & Amortization | $1,269,000 | $1,196,000 | $1,136,000 | $1,093,000 |
| EBITDA | $3,938,000 | $3,453,000 | $2,741,000 | $2,518,000 |
| % Margin | 23.5% | 24.2% | 21.6% | 21.2% |